JAC Advance Access originally published online on January 13, 2005
Journal of Antimicrobial Chemotherapy 2005 55(2):188-193; doi:10.1093/jac/dkh532
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.55 no.2 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved
Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital
Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario ‘Gregorio Marañón’, Doctor Esquerdo 47, 28006 Madrid, Spain
* Corresponding author. Tel: +34-91-58684-53; Fax: +34-91-5044906; Email: pmunoz{at}micro.hggm.es
Background:
Candida krusei fungaemia is an uncommon entity described in immunocompromised patients previously exposed to azole agents.
Methods:
From 1988 to 2003, 13 episodes of C. krusei fungaemia (2.3% of all fungaemias) were detected in our institution and compared with 39 Candida albicans controls. Susceptibility testing was carried out with the modified microdilution method according to NCCLS recommendations.
Results:
Underlying conditions were: HIV infection (4), haematological malignancies (4), organ transplantation (2), abdominal surgery (2) and lactose intolerance (1). Nine patients (69%) were not neutropenic. In comparison with C. albicans, patients with C. krusei infection had more commonly received antifungal agents (54% versus 15%, P=0.006), had a haematological disease (31% versus 3%, P=0.03), or a transplant (15% versus 3%, P=0.08), were on corticosteroids (47% versus 13%, P=0.01) and were neutropenic (31% versus 0%, P < 0.001). Patients with C. albicans had more surgical interventions (41% versus 15%, P=0.09) and bladder catheters (61% versus 31%, P=0.05). The most common origin for C. albicans was a catheter (41% versus 0%; P=0.006) whereas for C. krusei the most common origin was unknown (69% versus 20%; P=0.001). C. krusei presented more commonly with skin lesions in neutropenic patients (23% versus 5%; P=0.05). Multivariate analysis of these differential characteristics showed that the only factor that independently predicted the presence of C. krusei fungaemia was the administration of antifungal agents before the fungaemia (RR: 6.4; P=0.009; 95%CI 1.6–25.99). Overall mortality of C. krusei fungaemia was 38% (C. albicans 49%). Except for voriconazole (MIC90 0.125 mg/L), azoles and 5-flucytosine had poor activity against C. krusei, whereas amphotericin (MIC90 1 mg/L) and LY-303366 (MIC90 0.06 mg/L) showed good activity.
Conclusion:
C. krusei fungaemia incidence remains low despite widespread use of azoles. It may occur outside the setting of cancer patients with previous antifungal use. The presence of skin lesions should be a warning sign.
Keywords: candidosis , candidaemia , transplantation , HIV , neutropenia
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, E. Nagy, S. Dobiasova, M. Rinaldi, R. Barton, A. Veselov, and the Global Antifungal Surveillance Group Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 J. Clin. Microbiol., February 1, 2008; 46(2): 515 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fleck, A. Dietz, and H. Hof In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest J. Antimicrob. Chemother., April 1, 2007; 59(4): 767 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Jacobsen, N. A. R. Gow, M. C. J. Maiden, D. J. Shaw, and F. C. Odds Strain Typing and Determination of Population Structure of Candida krusei by Multilocus Sequence Typing J. Clin. Microbiol., February 1, 2007; 45(2): 317 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Caston, M. J. Linares, C. Gallego, A. Rivero, P. Font, F. Solis, M. Casal, and J. Torre-Cisneros Risk Factors for Pulmonary Aspergillus terreus Infection in Patients With Positive Culture for Filamentous Fungi Chest, January 1, 2007; 131(1): 230 - 236. [Abstract] [Full Text] [PDF]
|
|